ALKS Q3 2020 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$265M+3.8% YoY

Gross Profit

$222M83.7% margin

Operating Income

-$11M-4.0% margin

Net Income

-$134,000-0.1% margin

EPS (Diluted)

$-0.00

QoQ Revenue Growth

+7.1%

Cash Flow

Operating Cash Flow

$60M

Free Cash Flow

$54M

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$1.9B

Total Liabilities

$792M

Stockholders' Equity

$1.1B

Cash & Equivalents

$241M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$265M	$255M	+3.8%
Gross Profit	$222M	$213M	+4.2%
Operating Income	-$11M	-$54M	+80.1%
Net Income	-$134,000	-$53M	+99.7%

Revenue Segments

Product

$143M99%

License

$1M1%

Research And Development

$953,0001%